Bright Peak Therapeutics
PrivateLast Round
Series C
Jun 11, 2024
Total Funding Raised
$232M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Bright Peak Therapeutics is a biotechnology company that develops multifunctional precision immunotherapies for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Bright Peak Therapeutics Comparables
Compare Bright Peak Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 87% | |
| Asher Biotherapeutics | 84% | |
| Deka Biosciences | 83% |
For institutional investors. Book with your work email.
Bright Peak Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 11, 2024 | ||||
| Series B | Jun 10, 2021 | ||||
| Series A | Jul 28, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Bright Peak Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series C, Series B |
| Northleaf Capital Partners | Series C |
| KB Investment | Series C |
| KB Investment | Series C |
| Fidelity Management & Research Company | Series B, Series C |
| Versant Ventures | Series B, Series C, Series A |
| Alexandria Venture Investments | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 32% MoM.
- Apr 17, 2025
John Schmid appointed to the Board of Directors.
For institutional investors. Book with your work email.
Bright Peak Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Bright Peak Therapeutics's valuation, stock price, and market status.
Is Bright Peak Therapeutics a public or private company?
Bright Peak Therapeutics is a private company.
What is the current stock price of Bright Peak Therapeutics?
Bright Peak Therapeutics is a private company, so its shares have no public market price. Caplight tracks Bright Peak Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Bright Peak Therapeutics worth (valuation)?
Valuation information for Bright Peak Therapeutics is not publicly available.
Can I buy Bright Peak Therapeutics stock?
Bright Peak Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Bright Peak Therapeutics's last funding round?
Bright Peak Therapeutics's most recent funding round was Series C on June 11, 2024.
Who are the main investors in Bright Peak Therapeutics?
Key investors in Bright Peak Therapeutics include RA Capital Management, Versant Ventures, Johnson & Johnson Innovation - JJDC, Inc..
Will Bright Peak Therapeutics IPO soon?
No public IPO plans have been announced for Bright Peak Therapeutics.
How can I track Bright Peak Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Bright Peak Therapeutics's shares on secondary markets.